MP
ITCI

MSD Partners’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

MSD Partners’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-25,000
Closed -$394K – 37
2017
Q3 		$394K Buy
+25,000
New +$367K 0.01% 33

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MSD Partners's ITCI Position: Q4 2017 in Review

MSD Partners sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2017, closing a stake of 25,000 shares — an estimated $394K sold.

MSD Partners first reported a position in ITCI in Q3 2017 and held it in 1 quarter. The position peaked at $394K in Q3 2017. 131 funds tracked by Wall St. Rank hold ITCI as of Q4 2017.

  • MSD Partners reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2017 after selling out during the quarter.
  • MSD Partners sold 25,000 Intra-Cellular Therapies Inc. shares in Q4 2017, an estimated $394K.
  • MSD Partners first reported a position in Intra-Cellular Therapies Inc. in Q3 2017 and held it in 1 quarter.
  • MSD Partners's Intra-Cellular Therapies Inc. position peaked at $394K in Q3 2017.
  • 131 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2017.

Based on MSD Partners's 13F filing for Q4 2017, filed 14 Feb 2018.